Adaptimmune Announces Launch of US Subsidiary and Appointment of Gwen Binder-Scholl as VP of Operations
News Mar 08, 2011
Adaptimmune LLC has been set up to support the expansion of the company’s clinical activities in the US where it is already running a pilot trial in HIV and preparing to open three trials in different cancer indications later this month.
Adaptimmune has been progressing the development of its clinical programmes in T cell adoptive therapy using its enhanced T cell receptor technology since 2008. The company has been working closely with the translational research group from the University of Pennsylvania in Philadelphia with which it already has a pilot trial in HIV. Adaptimmune is now preparing to open three additional trials in multiple myeloma, metastatic melanoma and synovial sarcoma at multiple sites later this month.
Dr Gwen Binder-Scholl heads the new US company as Vice President of Operations and joins with extensive experience in T cell and gene therapy translational research, development, manufacture and regulatory affairs. She was formerly Director of Operations of the Translational Research Program at the University of Pennsylvania and before that Director of Scientific Affairs at Virxsys Corporation. Dr Binder-Scholl is a graduate of Wells College, New York with a PhD from John Hopkins University School of Medicine.
“We are tremendously fortunate to have attracted someone of Gwen’s calibre and experience to the company at this critical juncture in Adaptimmune’s development”, says James Noble, Adaptimmune’s CEO. “It has become increasingly important to us to support our expanding clinical activities in the US with the right resource and infrastructure; we see Gwen’s appointment as hugely significant in the first step towards this objective.”
”I am thrilled to have the opportunity to play a leading role in the clinical and commercial development of this promising technology platform, and to work with the superb scientific and business team at Adaptimmune Ltd,” says Gwen Binder-Scholl.
The new office will be located at the University Science Center in Philadelphia, alongside Adaptimmune’s strategic collaborators at the University of Pennsylvania.